Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2010-11-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gnosis P-1000 capsules
MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
Gnosis P-1000 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Gnosis M1500 capsules
MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
Gnosis M-1500 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
MenaQ7 M-1500 capsules
MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
MenaQ7 M-1500 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Gnosis P-1000 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MenaQ7 M-1500 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Gnosis P-1000 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Gnosis M-1500 capsules
The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
* MenaQ7 M-1500 capsule
* Gnosis P-1000 capsule
* Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal body weight and height (18.5 kg/m2 \< BMI \< 30 kg/m2)
* Stable body weight (weight gain or loss \< 3 kg in past 3 mo)
* Written consent to take part in the study
* Agreement to adhere to dietary restrictions required by the protocol
Exclusion Criteria
* Use of vitamin supplements containing vitamin K
* Soy allergy
* Pregnancy
* a history of) metabolic or gastrointestinal diseases including hepatic disorders
* Chronic degenerative and/or inflammatory diseases, e.g. diabetes mellitus, renal failure
* Use of oral anticoagulants
* Corticoid treatment
* Subjects with anaemia or subjects who recently donated blood or plasma
* Systemic treatment or topical treatment likely to interfere with coagulation metabolism (salicylates, antibiotics)
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cees Vermeer, PhD
Role: PRINCIPAL_INVESTIGATOR
VitaK BV Maastricht University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VitaK BV / Maastricht University Medical Center
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-3-017
Identifier Type: -
Identifier Source: org_study_id